Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mofegiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 7/20 | 0.96 |
| ▸ | MAOA known ✓ | P21397 | 5/20 | 0.96 |
| ▸ | AOC2 | O75106 | 5/20 | 0.96 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.96 |
| ▸ | DAO | P14920 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mofegiline SCHEMBL125286 | 1.00 | MAOB (0.96) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL343686 | 1.00 | MAOB (0.96) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL1295041 | 0.98 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL1295043 | 0.98 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL147813 | 0.98 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| Mofegiline SCHEMBL14005358 | 0.98 | MAOB (1.00) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295522 | 0.82 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295015 | 0.82 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1295016 | 0.82 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO | |
| SCHEMBL1294767 | 0.82 | MAOB (0.72) | MAOBAOC2MAOAAOC3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0642338-B1 | USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE | MERRELL PHARMA INC (US) | 1997-01-22 | — | — | EP | claimed |
| EP-0720475-A1 | TRANSDERMAL DEVICE CONTAINING (E)-2-(P-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-10 | — | — | EP | claimed |
| WO-1995008325-A1 | TRANSDERMAL DEVICE CONTAINING (E)-2-(P-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERRELL PHARMACEUTICALS INC. (US) | 1995-03-30 | — | — | WO | claimed |
| EP-0642338-A1 | USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE. | MERRELL DOW PHARMA (US) | 1995-03-15 | — | — | EP | claimed |
| EP-0639972-A1 | METHOD FOR PREVENTING ENDOTHELIUM DAMAGE IN MAMMALS AND FOR ALLEVIATING PAIN ASSOCIATED WITH GOUT AND ARTHRITIS | UNIVERSITY OF SASKATCHEWAN (CA) | 1995-03-01 | — | — | EP | claimed |
| WO-1993024120-A1 | USE OF (E)-2-(p-FLUOROPHENETHYL)-3-FLUOROALLYLAMINE IN THE TREATEMENT OF ALZHEIMER'S DISEASE | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-12-09 | — | — | WO | claimed |
| WO-1993023023-A1 | METHOD FOR PREVENTING ENDOTHELIUM DAMAGE IN MAMMALS AND FOR ALLEVIATING PAIN ASSOCIATED WITH GOUT AND ARTHRITIS | UNIVERSITY OF SASKATCHEWAN (CA) | 1993-11-25 | — | — | WO | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | Benevolentai Cambridge Limited (GB) | 2018-12-20 | — | — | US | disclosed |
| EP-3386494-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | Benevolentai Cambridge Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20060039866-A1 | Method for treating sleep-related breathing disorders | CYPRESS BIOSCIENCE, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20060039867-A1 | Method for treating sleep-related breathing disorders with setiptiline | CYPRESS BIOSCIENCE, INC. | 2006-02-23 | — | — | US | disclosed |
| US-5679854-A | Process for the preparation of (epsilon)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane and novel intermediate thereof | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0784604-A1 | PROCESSES FOR THE PREPARATION OF (E)-2-FLUOROMETHYLENE-4-(4-FLUOROPHENYL) BUTYLAMINE AND ALKALI METAL SALTS OF DIFORMYLAMIDE | HOECHST MARION ROUSSEL, INC. (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5599986-A | CRYSTALLIZATION YIELDS PURE FREE-FLOWING GRANULAR SOLIDS | HOECHST MARION ROUSSEL INC. (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996010003-A1 | PROCESSES FOR THE PREPARATION OF (E)-2-FLUOROMETHYLENE-4-(4-FLUOROPHENYL) BUTYLAMINE AND ALKALI METAL SALTS OF DIFORMYLAMIDE | HOECHST MARION ROUSSEL, INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| US-5488188-A | Process for the preparation of (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, novel processes for preparing an intermediate thereof, and novel intermediates thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | MAOB 937/4885MAOA 563/4885AOC2 59/4885 |
| US-20180360808-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | MAOB 937/4885MAOA 563/4885AOC2 59/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | MAOB 69/4885MAOA 83/4885AOC2 12/4885 |
| US-20060039867-A1 | Method for treating sleep-related breathing disorders with setiptiline | SETD1A, SETD7, SETD2 | MAOB 105/4885MAOA 53/4885AOC2 2731/4885 |
| US-20060039866-A1 | Method for treating sleep-related breathing disorders | DAZAP1, ZMYND8, CHAT | MAOB 361/4885MAOA 296/4885AOC2 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.